Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00815594
Verified December 2008 by Capital Medical University. Recruitment status was: Active, not recruiting
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Glaucoma patients after trabeculectomy whose bleb is hyperaemia
Bleb vascularity associated with increased scarring activity
Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery
the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.